Published 3 days ago • loading... • Updated 3 days ago

Can anything threaten Novo and Lilly’s obesity market dominance?

Summary by PharmaVOICE

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

2 Articles

All

Left

Center

Right

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

3 days ago

A large number of biotech and pharmaceutical companies are pushing obesity drugs into the spotlight. Ours is better than Novo's, say two competitors.

3 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources2

Leaning Left0Leaning Right0Center1Last Updated2 days agoBias Distribution

100% Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

PharmaVOICE broke the news in 3 days ago on Monday, April 21, 2025.

Sources are mostly out of (0)